Clinical trial · Interventional
Safety and Feasibility of Surgery After Conversion Therapy for Locally Advanced and Advanced NSCLC
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Lung cancer is one of the most common malignant tumors worldwide and the mortality ranks first in the world. In recent years, with the development of targeted therapy and immunotherapy, the overall survival of lung cancer patients has improved significantly. However, the inoperable advanced tumor remains the main reason for the poor prognosis of lung cancer. Thus, we aim to carry out this single-arm, prospective study to evaluate the safety and feasibility of surgery after conversion therapy for locally advanced and advanced non-small cell lung cancer.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Cancer | Malignant Neoplasm | CURATED_BROADER | 0.78 |
| Locally Advanced Cancer | Malignant Neoplasm | CURATED_BROADER | 0.78 |
| Pulmonary Neoplasm | Lung Neoplasm | PROBABILISTIC | 0.70 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Surgery | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Surgery after conversion therapy
- description
- Participants with locally advanced or advanced NSCLC who received first-line treatment have been evaluated as resectable after multidisciplinary discussion involving the department of thoracic surgery, respiratory medicine, radiology and oncology.
- interventionNames
- Procedure: Surgery
Primary outcomes (1)
- measure
- perioperative morbidity
- timeFrame
- postoperative in-hospital stay up to 30 days
- description
- rate of perioperative complications, mainly include: pneumonia, arrhythmia, incision infection, vocal cord paralysis, trachea cannula
Secondary outcomes (11)
- measure
- lymph nodes counts
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Volunteer to participate in the study with good compliance. Able to complete the observation and follow-up and have signed the informed consent; * More than 18 years old with no limit of sex; * Pathologically confirmed stage T4N0-3 or T1-3N2-3 NSCLC with residual tumor after first-line treatment (first-line chemotherapy, targeted therapy, immunotherapy, chemotherapy combined with immunotherapy, etc.) evaluated operable for radical resection; pathologically confirmed stage IVA NSCLC evaluated operable after first-line treatment (first-line chemotherapy, targeted therapy, immunotherapy, chemotherapy combined with immunotherapy, etc.); * ASA score: I-III; * Cardiopulmonary functions meet the requirements of radical operation for lung cancer with normal liver and kidney functions. Exclusion Criteria: * Serious heart, lung, liver and kidney dysfunction and unable to tolerate the operation; * Neurologic, mental illness or mental disorder which is hard to control, poor compliance, unable to cooperate or describe the treatment response; * Unable to receive radical resection; * Need of palliative or emergency operation due to lung abscess or hemoptysis; * Having received neoadjuvant chemoradiotherapy.
References
Publications (1)
- DERIVEDYan Y, Han Y, Niu Z, Zhang X, Li C, Cao Y, Yin Z, Zhu L, Hang J, Che J, Ren J, Xiang J, Chen K, Du H, Han D, Yang X, Zhang Y, Chen X, Jing H, Yu S, Wang X, Guo Z, Chen X, Luo F, Zhong W, Jin R, Li H. Conversion Surgery After Induction Therapy for Initially Unresectable Stage III Non-small Cell Lung Cancer: A Proof-of-Concept Trial. Ann Surg Oncol. 2026 Jul;33(7):6242-6251. doi: 10.1245/s10434-026-19461-z. Epub 2026 Mar 25. PMID 41880079